Adenosine vs Regadenoson Pharmacologic Stress Differs in Women with Suspected Coronary Microvascular Dysfunction: A Report from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) Study
- PMID: 36913201
- PMCID: PMC9997839
- DOI: 10.31487/j.cdm.2019.01.01
Adenosine vs Regadenoson Pharmacologic Stress Differs in Women with Suspected Coronary Microvascular Dysfunction: A Report from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) Study
Abstract
Background: Stress cardiac magnetic resonance (CMR) imaging with myocardial perfusion reserve index (MPRI) measurement has emerged as a noninvasive method for assessing coronary microvascular dysfunction (CMD) in the absence of obstructive coronary artery disease (CAD). Pharmacologic stress with adenosine or regadenoson is typically used with comparable coronary vasodilation, but higher unadjusted MPRI has been reported with regadenoson in healthy men. This difference has not been assessed in symptomatic or healthy women.
Methods: In a prospective cohort study, 139 symptomatic women with suspected CMD and no obstructive CAD underwent stress CMR and invasive coronary flow reserve (CFR) testing. Adenosine was the default vasodilator (n=99), while regadenoson was used if history of asthma or prior adenosine intolerance (n=40). Stress CMR was also performed in 40 age-matched healthy controls using adenosine (n=20) and regadenoson (n=20). Unpaired t-tests and analysis of covariance were performed to compare MPRI with adenosine and regadenoson in the symptomatic women and healthy controls.
Results: Compared to regadenoson cases, adenosine cases had lower invasive CFR (2.64±0.62 vs 2.94±0.68, p=0.01) and pharmacologic heart rate change (28±16 vs 38±15 bpm, p=0.0008). Unadjusted MPRI was lower in the adenosine compared to regadenoson cases (1.73±0.38 vs 2.27±0.59, p<0.0001). When adjusted for heart rate, rate-pressure-product, and invasive CFR, MPRI remained lower in the adenosine cases (p<0.0001). Invasive CFR to adenosine correlated with adenosine MPRI (r 0.17, p=0.02) but not regadenoson MPRI (r -0.14, p=0.19). There was no significant difference in MPRI in the controls who received adenosine vs regadenoson (2.27±0.33 vs 2.38±0.44, p=0.36).
Conclusion: In women undergoing stress CMR for suspected CMD, those who received adenosine had lower MPRI than those who received regadenoson. However, there were no differences in MPRI in the healthy controls. These findings suggest there may be physiologic differences in adenosine and regadenoson response in the coronary microcirculation of symptomatic women.
Keywords: coronary microvascular dysfunction; myocardial perfusion imaging; women.
Conflict of interest statement
Competing Interests: Puja K. Mehta has received research grants from Gilead and General Electric. Chrisandra Shufelt has received a research grant from Gilead. Daniel S. Berman has received research grants from Astellas Pharma US, Inc, Bayer Healthcare Pharmaceuticals, and Siemens Medical Solutions. C. Noel Bairey Merz would like to report funding from iRhythm, Abbott Diagnostics, and Sanofi.
Figures
References
-
- Thomson LE, Wei J, Agarwal M, Haft Baradaran A, Shufelt C et al. (2015) Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute-sponsored study from the Women’s Ischemia Syndrome Evaluation. Circ Cardiovasc Imaging 8. [Crossref] - PMC - PubMed
-
- Doyle M, Weinberg N, Pohost GM, Bairey Merz CN, Shaw LJ et al. (2010) Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women’s Ischemia Syndrome Evaluation) study. JACC Cardiovasc Imaging 3: 1030–1036. [Crossref] - PMC - PubMed
-
- Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD et al. (2007) Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 14: 645–658. [Crossref] - PubMed
Grants and funding
- N01 HV068161/HV/NHLBI NIH HHS/United States
- U01 HL064829/HL/NHLBI NIH HHS/United States
- R03 AG032631/AG/NIA NIH HHS/United States
- T32 HL069751/HL/NHLBI NIH HHS/United States
- K23 HL125941/HL/NHLBI NIH HHS/United States
- UL1 TR000124/TR/NCATS NIH HHS/United States
- U01 HL064924/HL/NHLBI NIH HHS/United States
- UL1 TR001427/TR/NCATS NIH HHS/United States
- R01 HL033610/HL/NHLBI NIH HHS/United States
- M01 RR000425/RR/NCRR NIH HHS/United States
- UM1 HL087366/HL/NHLBI NIH HHS/United States
- K23 HL105787/HL/NHLBI NIH HHS/United States
- UL1 TR001881/TR/NCATS NIH HHS/United States
- R01 HL090957/HL/NHLBI NIH HHS/United States
- UL1 TR000064/TR/NCATS NIH HHS/United States
- N01 HV068163/HL/NHLBI NIH HHS/United States
- N01 HV068164/HV/NHLBI NIH HHS/United States
- R01 HL056921/HL/NHLBI NIH HHS/United States
- N01 HV068162/HL/NHLBI NIH HHS/United States
- R37 HL033610/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous